Post-Finasteride Syndrome: Pharmacists Must Lead the Conversation on Patient Safety

In 2025, the European Medicines Agency (EMA) confirmed that finasteride, a medication commonly prescribed for androgenetic alopecia, is associated with suicidal ideation, a concern that patient advocacy groups had been raising for over a decade. Following this confirmation, both the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare products Regulatory Agency (MHRA) took action to address these safety concerns. The article emphasizes the crucial role pharmacists must play in leading conversations about patient safety regarding finasteride use.